secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLOBUS MEDICAL INC (GMED)
CIK:        0001237831
Form:       8-K
Filed at:   2021-08-04T23:59:59+00:00
Accession:  0001562762-21-000296
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Globus Medical Q2 revenue $251M (+68.6% YoY); raises FY2021 guidance to $950M sales, $1.89-2.00 EPS
--------------------------------------------------------------------------------

- Q2 worldwide net sales of $251.0M, up 68.6% YoY; GAAP net income $41.5M (16.6% of sales), up 299.4% YoY.
- GAAP diluted EPS $0.40, Non-GAAP diluted EPS $0.56, compared to ($0.21) and $0.07 in Q2 2020 respectively.
- U.S. Spine business grew ~64% YoY; Enabling Technologies revenue $21M (nearly 4x Q2 2020).
- Raised FY2021 guidance: net sales to $950M (from $925M) and non-GAAP diluted EPS to $1.89-$2.00.
- Cash and marketable securities $914.2M, no debt; generated $59.2M operating cash flow, $50.8M free cash flow in Q2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1237831/000156276221000296/0001562762-21-000296-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1237831/000156276221000296/gmed-20210804x8k.htm
  HTML page:      https://secwatch.observer/filing/0001562762-21-000296

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer